Last reviewed · How we verify
Synflorix (Single Dose)
Synflorix is a pneumococcal conjugate vaccine that stimulates the body's immune response to protect against Streptococcus pneumoniae infections.
Synflorix is a pneumococcal conjugate vaccine that stimulates the body's immune response to protect against Streptococcus pneumoniae infections. Used for Prevention of invasive pneumococcal disease and pneumonia caused by Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
At a glance
| Generic name | Synflorix (Single Dose) |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Conjugate vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious diseases |
| Phase | Phase 3 |
Mechanism of action
Synflorix contains 10 pneumococcal serotypes and is designed to provide protection against invasive pneumococcal disease and pneumonia. The vaccine works by inducing the production of antibodies that recognize and neutralize the pneumococcal capsular polysaccharides, thereby preventing the bacteria from causing disease.
Approved indications
- Prevention of invasive pneumococcal disease and pneumonia caused by Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F
Common side effects
- Pain, redness, swelling, or bruising at the injection site
- Fever
- Fatigue
Key clinical trials
- Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe (PHASE3)
- Evaluation of PCV Schedules in a Naive Population in Vietnam (PHASE4)
- Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV (PHASE1, PHASE2)
- Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants (PHASE3)
- Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™ (PHASE3)
- Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in Toddlers (PHASE1)
- Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine (PHASE3)
- Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Synflorix (Single Dose) CI brief — competitive landscape report
- Synflorix (Single Dose) updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI